DrugDashboards

Foster and Thrive Fiber Laxative 147

Calcium polycarbophil · CALCIUM POLYCARBOPHIL 625 mg/1 · Tablet · Oral · Strategic Sourcing Services LLC

NDC 70677-1083-01 · 90 TABLET in 1 BOTTLE · OTC MONOGRAPH DRUG · View full market →

The short version

14 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $0.0584 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.

How Part D pricing works →

NADAC price per unit

$0$0.025$0.05$0.075Oct 2023Sep 2026$0.0584
36 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$1.75
#90 count
$5.25

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$7,572
603 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for calcium polycarbophil (oral solid) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Xywav and Xyrem

Regulatory

Application
M007
TE code
Approval date
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Calcium polycarbophil (Tablet)

LabelerStrengthFirst seenLast seen
Medtech Products Inc.CALCIUM POLYCARBOPHIL 625 mg/1Sep 3, 2026Sep 3, 2026
Chain Drug Marketing Association Inc.CALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Citragen Pharmaceuticals, Inc.CALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Discount Drug Mart, IncCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Foundation Consumer BrandsCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Gendose Pharmaceuticals, LLCCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
GoodSenseCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Numark Brands, IncCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Strategic Sourcing Services LLCCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Target Corporation.CALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Topco Associates, LLCCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
United Natural Foods, Inc. Dba UnfiCALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Wal-Mart Stores, Inc.CALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Sep 2, 2026
Magno-Humphries, Inc.CALCIUM POLYCARBOPHIL 625 mg/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Foster and Thrive Fiber Laxative 147 — NDC 70677-1083-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70677108301.

Free to cite with attribution — see how the data is put together.